Elexacaftor, Tezacaftor and Ivacaftor and Revefenacin
Determining the interaction of Elexacaftor, Tezacaftor and Ivacaftor and Revefenacin and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:Consumer information for this interaction is not currently available.GENERALLY AVOID: Coadministration of revefenacin with inhibitors of organic anion transporting polypeptide (OATP) 1B1 and/or 1B3 may increase systemic exposure to its active metabolite, which has been reported to be a substrate of the hepatic uptake transporters. No pharmacokinetic data are available, but increased anticholinergic adverse effects such as mydriasis, blurred vision, heat intolerance, fever, dry mouth, tachycardia, urinary retention, constipation, and glaucoma (onset or exacerbation) may occur. In study patients, revefenacin was rapidly converted to its active metabolite following inhaled administration, and plasma exposures of the metabolite exceeded those of revefenacin by approximately 4- to 6-fold. The activity of the metabolite at target muscarinic receptors is approximately one-third to one-tenth that of revefenacin and could potentially contribute to systemic antimuscarinic effects at therapeutic doses. MANAGEMENT: Concomitant use of revefenacin with OATP 1B1 and/or 1B3 inhibitors is not recommended. References "Product Information. Yupelri (revefenacin)." Mylan Specialty, Morgantown, WV.
Professional:GENERALLY AVOID: Coadministration of revefenacin with inhibitors of organic anion transporting polypeptide (OATP) 1B1 and/or 1B3 may increase systemic exposure to its active metabolite, which has been reported to be a substrate of the hepatic uptake transporters. No pharmacokinetic data are available, but increased anticholinergic adverse effects such as mydriasis, blurred vision, heat intolerance, fever, dry mouth, tachycardia, urinary retention, constipation, and glaucoma (onset or exacerbation) may occur. In study patients, revefenacin was rapidly converted to its active metabolite following inhaled administration, and plasma exposures of the metabolite exceeded those of revefenacin by approximately 4- to 6-fold. The activity of the metabolite at target muscarinic receptors is approximately one-third to one-tenth that of revefenacin and could potentially contribute to systemic antimuscarinic effects at therapeutic doses.
MANAGEMENT: Concomitant use of revefenacin with OATP 1B1 and/or 1B3 inhibitors is not recommended.
- "Product Information. Yupelri (revefenacin)." Mylan Specialty, Morgantown, WV.
Generic Name: elexacaftor / ivacaftor / tezacaftor
Brand name:
Synonyms: n.a.
Generic Name: revefenacin
Brand name: Yupelri
Synonyms: Revefenacin (inhalation)
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Elexacaftor, Tezacaftor and Ivacaftor-Revefenacin inhalation
- Elexacaftor, Tezacaftor and Ivacaftor-Reversol
- Elexacaftor, Tezacaftor and Ivacaftor-Revesta
- Elexacaftor, Tezacaftor and Ivacaftor-Revestive
- Elexacaftor, Tezacaftor and Ivacaftor-Revex
- Elexacaftor, Tezacaftor and Ivacaftor-ReVia
- Revefenacin-Elfolate
- Revefenacin-Elidel
- Revefenacin-Elidel Topical
- Revefenacin-Eligard
- Revefenacin-Eliglustat
- Revefenacin-Eliglustat Tartrate